<DOC>
<DOCNO>1050107_business_story_4223149.utf8</DOCNO>
<TEXT>


The Telegraph - Calcutta : Business

 Glenmark pops 1:1 bonus

 OUR SPECIAL CORRESPONDENT 

 Mumbai, Jan. 6: Mumbai-based Glenmark Pharmaceuticals has cheered shareholders by announcing a 1:1 bonus issue.

 The bonus was approved by directors at a board meeting held today. Glenmark will now seek shareholders? approval for the issue. The company has an equity capital of Rs 11.85 crore.

 ?The bonus issue will help us share the benefits of robust growth and performance with shareholders,? said Glenn Saldanha, managing director and CEO of Glenmark.

 News of the bonus led to the Glenmark scrip rising to an intra-day high of Rs 541 after opening at Rs 509.90 on the Bombay Stock Exchange today. 

 However, the scrip was affected by the volatility and profit booking that gripped the equity market. It plummeted to a days low of Rs 477, before recovering to Rs 480.95, a loss of over Rs 22 against its last close.

 The Rs 381-crore Glenmark Pharma is present in the areas of dermatology, gynaecology, respiratory, gastrointestinal and lifestyle diseases like diabetes and cardiology. The company is the market leader in dermatology and respiratory segments with brands like Candid B and Ascoril, respectively. 




</TEXT>
</DOC>